Pershing Square invests more in Valeant after controversy

William Ackman’s Pershing Square Capital Management LP disclosed an increased stake in Valeant Pharmaceuticals, a move that comes after the hedge-fund manager said he had taken advantage of the beaten-down market for the stock to build up his position.